Treatment · Autonomic
Ivabradine
A drug that calms a racing heart without lowering blood pressure, which makes it well suited to POTS. Post-COVID POTS has been studied specifically, and ivabradine shows one of the better response rates among POTS medications.
Short version: ivabradine slows the heart rate directly without dropping blood pressure, useful in POTS when beta-blockers are not tolerated. A post-COVID trial has tested it.
Slowing the heart without dropping pressure
Ivabradine slows the heart's natural pacemaker directly, lowering a racing rate without lowering blood pressure, which is useful when beta-blockers drop pressure too much.1
What the evidence says
In POTS reviews ivabradine shows one of the higher rates of symptomatic improvement, and a nested randomized trial in post-COVID POTS (COVIVA) tested it specifically. Its limited effect on breathing is an advantage for people with breathlessness.2, 3
favourable signal post-COVID RCT done
Where it fits
It is often considered when the heart rate is the main problem and beta-blockers are not tolerated. Availability and cost vary by country. As always it sits alongside fluids, salt, and compression for POTS.
What taking it is actually like
It is a tablet, usually taken twice a day. Because it slows heart rate without lowering blood pressure, it tends to suit a racing heart on standing. The distinctive side effect is brief visual brightening or halos (“luminous phenomena”), usually mild, early, and reversible; it can also slow the heart too much or, less often, nudge the rhythm out of step. Heart rate and rhythm are checked, and it is avoided in some heart conditions and in pregnancy. Dose and suitability are individual — this is not a dosing guide.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- How ivabradine compares with beta-blockers long-term.
- Who responds best.
- Cost and access barriers.
References
Every reference is free to read in full.